GuidelineThe American journal of gastroenterology2017
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Guideline in The American journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 6 registered trials, which are not on this map. Cited by 684 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura
Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy?
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction (HELP-MI SWEDEHEART)
Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days
Efficacy of Vonoprazan Based Dual and Triple Therapy for Naive Patient With Helicobacter Pylori Infection
Who cites it
684 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,568 citations in OpenAlex.
- Functional dyspepsia overlapping with other functional gastrointestinal disorders: a bibliometric and visualization analysis.Frontiers in medicine · 2026Pooled it
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Efficacy analysis of folic acid in chronic atrophic gastritis with Helicobacter pylori infection: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Quality indicators for upper GI endoscopy.Gastrointestinal endoscopy · 2025Guideline
- Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.PloS one · 2025Pooled it
- Minocycline in the eradication ofWorld journal of gastroenterology · 2024Pooled it
- The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses.Scientific reports · 2024Pooled it
- Efficacy and safety of seven Chinese patent medicines combined with conventional triple/quadruple therapy forBMJ open · 2024Pooled it
- Treatment ofWorld journal of gastroenterology · 2024Pooled it
- Pooled it
- Insights intoFrontiers in microbiology · 2024Pooled it
- Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study.Scientific reports · 2026Trial
- Early versus Late Eradication ofGut and liver · 2025Trial
- Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy forWorld journal of gastroenterology · 2025Trial
- Eradication ofHealth technology assessment (Winchester, England) · 2025Trial
- Vonoprazan-based therapy versus standard regimen for Helicobacter pylori infection management in Egypt: an open-label randomized controlled trial.Scientific reports · 2025Trial
- Amoxicillin high-dose dual therapy forWorld journal of gastroenterology · 2025Trial
- Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-ResistantGut and liver · 2024Trial
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.Nature medicine · 2024Trial
- Culture-based susceptibility-guided tailored versus empirical concomitant therapy as first-line Helicobacter pylori treatment: A randomized clinical trial.United European gastroenterology journal · 2024Trial
624 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) infection is a common worldwide infection that is an important cause of peptic ulcer disease and gastric cancer. H. pylori may also have a role in uninvestigated and functional dyspepsia, ulcer risk in patients taking low-dose aspirin or starting therapy with a non-steroidal anti-inflammatory medication, unexplained iron deficiency anemia, and idiopathic thrombocytopenic purpura. While choosing a treatment regimen for H. pylori, patients should be asked about previous antibiotic exposure and this information should be incorporated into the decision-making process. For first-line treatment, clarithromycin triple therapy should be confined to patients with no previous history of macrolide exposure who reside in areas where clarithromycin resistance amongst H. pylori isolates is known to be low. Most patients will be better served by first-line treatment with bismuth quadruple therapy or concomitant therapy consisting of a PPI, clarithromycin, amoxicillin, and metronidazole. When first-line therapy fails, a salvage regimen should avoid antibiotics that were previously used. If a patient received a first-line treatment containing clarithromycin, bismuth quadruple therapy or levofloxacin salvage regimens are the preferred treatment options. If a patient received first-line bismuth quadruple therapy, clarithromycin or levofloxacin-containing salvage regimens are the preferred treatment options. Details regarding the drugs, doses and durations of the recommended and suggested first-line and salvage regimens can be found in the guideline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.